An Imaging Pilot Study of 18F-fluoro-3'-Deoxy-3'-L-fluorothymidine (18F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine
The objective of this pilot study are (i) to compare response to chemotherapy, time to
disease progression and overall survival in patients with pancreatic cancer who will be
treated with gemcitabine who demonstrate 18F-FLT uptake to those patients who do not
demonstrate 18F-FLT uptake; (ii) to correlate 18F-FLT uptake with hENT1 expression with
biopsy samples where available; (iii)to determine the presence or absence of uptake, the
relative uptake score (RUS) and tumour to background ratios of 18F-FLT in patients with known
carcinoma of the pancreas and assess this uptake in relation to time to disease progression;
and (iv) to demonstrate the safety of 18F-FLT manufactured at the Edmonton PET Centre.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society